M Ventures
€600m
Fund allocation
2009
Inception of M Ventures
90+
Total investments
Entrepreneurs at heart in Biotechnology and Technology
M Ventures is the strategic, corporate venture capital fund of Merck KGaA, Darmstadt, Germany, investing in Biotechnology and Technology. We cover the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.
We invest - with dual strategic and financial foci - into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence.
We take an active role in our portfolio companies and team up with entrepreneurs and co-investors to translate innovation towards commercial success.
“M Ventures has been the guardian angel of Calypso Biotech since its birth!”
Calypso Biotech is an immunotherapy biotech company, spin-off from Merck KGaA, Darmstadt, Germany, that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs.
“They never stop asking the hard questions—the kind worth answering to advance our innovation.”
ImmuneBridge is amplifying nature's innate intelligence to develop allogeneic immunotherapies for cancer.
“They add significant business value on a monthly basis and have proven to be very founder friendly.”
Tignis combines the precise insights of physics with the most advanced AI and ML data science to give semiconductor equipment manufacturers, wafer fabs, and components and materials suppliers unprecedented automation and process control.
“With their commitment to our project, fundraising during seed and series A investment rounds became much easier.”
Solving the holy grail of OLED research: an efficient AND stable, deep-blue emitter for next gen OLED displays
“MV investment is very practical and collaborative, always putting the best interests of the company at the forefront. Furthermore, they are always available and willing to help.”
MemryX is a fabless semiconductor company that designs and sells innovative Edge AI processors
“MV investment provides scientific and business insights relevant to a startup.”
Outrun Therapeutics is an E3 ligase inhibitor company leveraging its activity-based probe as a platform to discover and develop novel therapeutics for cancer and other relevant diseases.
“Hands on when they need to be. Hands off when they need to be. Always supportive. That’s M Ventures!”
At Neurable, we’re translating brain activity into simple, actionable insights you can use in your everyday life. After all, your brain knows you best.
”Unfortunately there is no quote by Rob Devlin. Unfortunately there is no quote by Metalenz.“
Metalenz is a fabless semiconductor optics company on a mission to revolutionize optical sensing with metasurface technology.
Latest News
-
Abselion raises £6.6 million led by M Ventures to bring disruptive at-line protein analyser, Amperia, to market
-
Nouscom Completes Patient Enrollment of Randomized Phase 2 Study Evaluating NOUS-209, an Off-the-Shelf Neoantigen Immunotherapy, in dMMR/MSI Metastatic Colorectal Cancer
-
IonKraft secures € 3.5 M equity funding to fuel circular economy in packaging
-
Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates
-
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens
-
PictorLabs Raises $30 Million in Series B Funding to Accelerate AI-Powered Virtual Staining Technology
